Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Array, Pierre Fabre Partner On Cancer

by Lisa M. Jarvis
November 23, 2015 | A version of this story appeared in Volume 93, Issue 46

Pierre Fabre will pay Array BioPharma $30 million up front for the right to develop two cancer compounds, binimetinib and encorafenib, in Europe, Asia, and Latin America. In December, Array regained the rights to binimetinib, a MEK inhibitor in Phase III trials in ovarian cancer and melanoma, from Novartis, which had to divest the compound as a condition of acquiring GlaxoSmithKline’s oncology business. Novartis later sold Array the rights to encorafenib, a BRAF inhibitor in Phase III studies in ovarian cancer. Pierre Fabre will pay for 40% of future development costs of the two drugs.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.